TITLE

Stereospecific pharmacokinetic characterisation of phenprocoumon metabolites, and mass-spectrometric identification of two novel metabolites in human plasma and liver microsomes

AUTHOR(S)
Kammerer, Bernd; Kahlich, Rainer; Ufer, Mike; Schenkel, Andreas; Laufer, Stefan; Gleiter, Christoph H.
PUB. DATE
November 2005
SOURCE
Analytical & Bioanalytical Chemistry;Nov2005, Vol. 383 Issue 6, p909
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Phenprocoumon belongs to the group of vitamin K antagonists (VKAs), for example warfarin and acenocoumarol. It is widely used for therapeutic anticoagulation and clinically administered as a racemate. Both enantiomers are partially metabolized by the polymorphic CYP2C9 enzyme. The pharmacokinetics are, however, substantially less dependent on CYP2C9 activity or genotype than for other CYP2C9-metabolised VKAs, and pharmacokinetic differences for the enantiomers are only minor. We have investigated the stereospecific pharmacokinetics of the monohydroxylated phenprocoumon metabolites in human plasma by achiral�chiral LC�LC�MS�MS coupling. In addition to the known metabolites, 4'-, 6-, and 7-hydroxyphenprocoumon, two other monohydroxylated metabolites (M1 and M2) were detected in plasma and human liver microsomal incubations. One of these was identified as 2'-hydroxyphenprocoumon by comparison with synthetic standards; the other seemed to be a side-chain-hydroxylated derivative. Analysis of enantiomeric metabolite ratios after a single oral dose of phenprocoumon revealed changes over time with an overall preponderance of the respective ( R) enantiomers. The minor role of CYP2C9 in 4'-hydroxy-PPC formation and the effect of CYP2C9 genotype for ( S)-6- and ( S)-7-hydroxy-PPC were confirmed. M1 and M2 are formed highly stereoselectively, without dependence on CYP2C9 genotype. These may be interpreted as alternative metabolic pathways that render phenprocoumon less dependent on CYP2C9 activity or genotype.
ACCESSION #
18813193

 

Related Articles

  • Association of CYP2B6, CYP3A5, and CYP2C19 Genetic Polymorphisms With Sibutramine Pharmacokinetics in Healthy Korean Subjects. Kim, K. A.; Song, W. K.; Park, J. Y. // Clinical Pharmacology & Therapeutics;Nov2009, Vol. 86 Issue 5, p511 

    We assessed the association of CYP2B6, CYP3A5, and CYP2C19 polymorphisms with sibutramine pharmacokinetics. Forty six healthy male subjects were enrolled, and their CYP2B6 (*4 and *6), CYP3A5 (*3), and CYP2C19 (*2, and *3) genotypes were analyzed. After a single 15-mg dose of sibutramine was...

  • Pharmacokinetic differences between the enantiomers of lansoprazole and its metabolite, 5-hydroxylansoprazole, in relation to CYP2C19 genotypes. Miura, M.; Tada, H.; Yasui-Furukori, N.; Uno, T.; Sugawara, K.; Tateishi, T.; Suzuki, T. // European Journal of Clinical Pharmacology;Nov2004, Vol. 60 Issue 9, p623 

    Objective: The purpose of this study was to elucidate the pharmacokinetics of each enantiomer of lansoprazole and 5-hydroxylansoprazole in three different CYP2C19 genotype groups of Japanese subjects. Methods: Healthy subjects (n = 18), of whom 6 were homozygous extensive metabolizers (homEMs),...

  • A Pharmacokinetic-Pharmacodynamic Model for Predicting the Impact of CYP2C9 and VKORC1 Polymorphisms on Fluindione and Acenocoumarol During Induction Therapy. Verstuyft, Céline; Delavenne, Xavier; Rousseau, Alexandra; Robert, Annie; Tod, Michel; Diquet, Bertrand; Lebot, Martine; Jaillon, Patrice; Becquemont, Laurent // Clinical Pharmacokinetics;2012, Vol. 51 Issue 1, p41 

    Background and Objective: Vitamin K epoxide reductase complex, subunit 1 (VKORC1) and cytochrome P450 2C9 (CYP2C9) polymorphisms are taken into account when predicting a safe oral dose of coumarin anticoagulant therapy, but little is known about the effects of genetic predictors on the response...

  • Potato steroidal glycoalkaloid levels and the expression of key isoprenoid metabolic genes. Krits, Pinchas; Fogelman, Edna; Ginzberg, Idit // Planta;Dec2007, Vol. 227 Issue 1, p143 

    The potato steroidal glycoalkaloids (SGA) are toxic secondary metabolites, and their total content in tubers should not exceed 20 mg/100 g fresh weight. The two major SGA in cultivated potato ( Solanum tuberosum) are α-chaconine and α-solanine. SGA biosynthetic genes and the genetic...

  • Enteric Microbiome Metabolites Correlate with Response to Simvastatin Treatment. Kaddurah-Daouk, Rima; Baillie, Rebecca A.; Zhu, Hongjie; Zeng, Zhao-Bang; Wiest, Michelle M.; Nguyen, Uyen Thao; Wojnoonski, Katie; Watkins, Steven M.; Trupp, Miles; Krauss, Ronald M. // PLoS ONE;2011, Vol. 6 Issue 10, p1 

    Although statins are widely prescribed medications, there remains considerable variability in therapeutic response. Genetics can explain only part of this variability. Metabolomics is a global biochemical approach that provides powerful tools for mapping pathways implicated in disease and in...

  • Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Desta, Z.; Zhao, X.; Shin, J-G.; Flockhart, D.A.; Desta, Zeruesenay; Zhao, Xiaojiong; Shin, Jae-Gook; Flockhart, David A // Clinical Pharmacokinetics;Sep2002, Vol. 41 Issue 12, p913 

    Cytochrome P450 2C19 (CYP2C19) is the main (or partial) cause for large differences in the pharmacokinetics of a number of clinically important drugs. On the basis of their ability to metabolise (S)-mephenytoin or other CYP2C19 substrates, individuals can be classified as extensive metabolisers...

  • 1935.  // History of Science & Technology;2004, p518 

    The article presents several developments in science and technology in 1935, including the discovery of vitamin K by Henrik Dam.

  • HEMORRAGIA POR DICUMARÍNICOS: INCIDENCIA, FACTORES DE RIESGO Y COMPARACIÓN CON LOS NUEVOS ANTICOAGULANTES ORALES. KORIN, JORGE // Medicina (Buenos Aires);Oct2012, Vol. 72 Issue 5, p419 

    Bleeding is the main complication of oral anticoagulants, anti-vitamin K or new drugs such as anti-factor Xa or anti-thrombin agents. Risk factors associated with bleeding during warfarin therapy are discussed. For the new drugs no published data is available yet. Comparative frequencies of...

  • Ultrasound bone mass in patients undergoing chronic therapy with oral anticoagulants. Rey-Sanchez, Purificacion; Lavado-Garcia, Jesus; Canal-Macias, Maria; Rodriguez-Dominguez, Maria; Bote-Mohedano, Jose; Pedrera-Zamorano, Juan; Lavado-Garcia, Jesus Maria; Canal-Macias, Maria Luz; Rodriguez-Dominguez, Maria Trinidad; Bote-Mohedano, Jose Luis; Pedrera-Zamorano, Juan Diego // Journal of Bone & Mineral Metabolism;Sep2011, Vol. 29 Issue 5, p546 

    The purpose of this study was to assess the effects of chronic oral anticoagulant (OAC) treatment on bone mass using quantitative ultrasound (QUS) techniques. A total of 120 patients (47 women and 73 men) undergoing treatment with OAC and 57 healthy subjects (27 women and 30 men) participated in...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics